Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
New I-MAK Report Exposes Patent Abuse and Market Monopolization Behind GLP-1 Drug Prices The Heavy Price of GLP-1 Drugs reveals how pharmaceutical companies are exploiting the patent system, delaying competition, and driving up costs for patients NEW YORK, April 10, 2025 (Newswire.com) - Today, The Initiative for Medicines, Access, and Knowledge (I-MAK) released a groundbreaking new report, The Heavy Price of GLP-1 Drugs: How Financialization Drives Pharmaceutical Patent Abuse and Health Inequities for GLP-1 Therapies
This pattern is not unique to GLP-1 medications
GLP-1 medications, or glucagon-like peptide-1 receptor agonists, treat type 2 diabetes and, in some cases, obesity
The difference is professional oversight: board-certified nurses monitoring your response, adjusting doses, and ensuring safety every step of the way
33 Exosomes are a class of small extracellular vesicles (30100 nm) released by most cells
